SCHEMBL2908049

SCHEMBL2908049

CC(C)(C)OC(=O)N1CCN(C(c2ccccc2)c2c[nH]nc2-c2ccco2)CC1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.46
KDM4E B2RXH2 2/20 0.46
NPC1 O15118 1/20 0.46
USP2 O75604 1/20 0.46
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
RAB9A P51151 1/20 0.46
ABCB1 P08183 2/20 0.45
ABCG2 Q9UNQ0 1/20 0.45
CYP3A4 P08684 2/20 0.44
CYP3A5 P20815 2/20 0.44
ADORA2A P29274 3/20 0.43
ADORA1 P30542 1/20 0.43
ADORA3 P0DMS8 1/20 0.42
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
GPR119 Q8TDV5 1/20 0.41
MGLL Q99685 1/20 0.41
GLS O94925 1/20 0.40
TSHR P16473 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902713 0.90 CYP3A4 (0.42) ALDH1A1KDM4ENPC1USP2LMNA
SCHEMBL2908989 0.89 KMT2A (0.44) ALDH1A1KDM4ENPC1ABCB1ABCG2
SCHEMBL2905283 0.87 ALDH1A1 (0.52) ALDH1A1KDM4ENPC1USP2LMNA
SCHEMBL2904791 0.86 CYP3A4 (0.42) ALDH1A1KDM4ENPC1USP2LMNA
SCHEMBL2901965 0.85 SCD5 (0.42) ALDH1A1KDM4ENPC1USP2LMNA
SCHEMBL2909633 0.79 MEN1 (0.50) ALDH1A1KDM4ENPC1USP2LMNA
SCHEMBL2902824 0.79 MAPT (0.47) ALDH1A1KDM4ENPC1USP2LMNA
SCHEMBL2902229 0.78 SMN1; SMN2 (0.47) ALDH1A1KDM4ENPC1USP2LMNA
SCHEMBL2905980 0.78 ALDH1A1 (0.42) ALDH1A1KDM4ENPC1USP2LMNA
SCHEMBL4013471 0.77 KMT2A (0.67) ALDH1A1KDM4ENPC1CYP3A4KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A ALDH1A1 1336/4885KDM4E 3489/4885NPC1 1748/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.